COVID-19 Global Updates & Resources

TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be performed. IL2 is a cytokine signaling molecule that can limit immune suppression.